# The Supreme Court turned away appeals from six pharmaceutical companies.

*biotech · news · 2026-05-18 · The Boston Globe*

## Key points

- The Supreme Court declined to hear pharmaceutical companies' constitutional challenges to Medicare drug price negotiations.
- Novo Nordisk's Ozempic and Wegovy will face a 71 percent Medicare discount starting in 2027.
- The program is expected to generate $12 billion in Medicare savings on 15 drugs compared to 2024 prices.
- Federal appeals courts have so far uniformly upheld the legality of the Medicare price negotiation program.
- Drugmakers argue they must accept the government's price or leave half the US market, an unrealistic choice.

**Companies:** AstraZeneca Plc, Johnson & Johnson, Bristol Myers Squibb Co., Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim Pharmaceuticals Inc.
**Countries:** United States

[Read the full story on The Boston Globe](https://www.bostonglobe.com/2026/05/18/business/drug-companies-supreme-court-price-negotiation-law/)

---

Canonical: https://newsio.io/n/3168efd7-11fd-44d9-ba1a-a8a919175845/the-supreme-court-turned-away-appeals-from-six-pharmaceutical-companies-the-rebu
Summarized by Newsio from The Boston Globe. https://newsio.io/how-it-works